{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:07:37Z","timestamp":1793243257043,"version":"4.5.0"},"reference-count":244,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1038\/s41575-024-01021-z","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T08:27:18Z","timestamp":1733732838000},"page":"173-190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Current and emerging strategies for the prevention of hepatocellular carcinoma"],"prefix":"10.1038","volume":"22","author":[{"given":"Yee Hui","family":"Yeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-8618","authenticated-orcid":false,"given":"Manal","family":"Abdelmalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-2023","authenticated-orcid":false,"given":"Seema","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Moylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz","family":"Rodriquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3585-3727","authenticated-orcid":false,"given":"Augusto","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-9825","authenticated-orcid":false,"given":"Ju Dong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"1021_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"1021_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang, J. D. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 16, 589\u2013604 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1021_CR3","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay, H. et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J. Hepatol. 77, 1598\u20131606 (2022).","journal-title":"J. Hepatol."},{"key":"1021_CR4","unstructured":"International Agency for Research on Cancer. Cancer today. Global Cancer Observatory https:\/\/gco.iarc.who.int\/today (2024)."},{"key":"1021_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","volume":"161","author":"H Rumgay","year":"2022","unstructured":"Rumgay, H. et al. Global, regional and national burden of primary liver cancer by subtype. Eur. J. Cancer 161, 108\u2013118 (2022).","journal-title":"Eur. J. Cancer"},{"key":"1021_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.gastha.2021.10.010","volume":"1","author":"YT Lee","year":"2022","unstructured":"Lee, Y. T. et al. Increasing incidence of intrahepatic cholangiocarcinoma relative to hepatocellular carcinoma in the United States. Gastro Hep Adv. 1, 121\u2013124 (2022).","journal-title":"Gastro Hep Adv."},{"key":"1021_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","volume":"7","author":"GBD 2019 Hepatitis B Collaborators.","year":"2022","unstructured":"GBD 2019 Hepatitis B Collaborators.Global, regional, and national burden of hepatitis B, 1990\u20132019: systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol. Hepatol. 7, 796\u2013829 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1021_CR8","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2020.06.011","volume":"73","author":"GV Papatheodoridis","year":"2020","unstructured":"Papatheodoridis, G. V. et al. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J. Hepatol. 73, 1037\u20131045 (2020).","journal-title":"J. Hepatol."},{"key":"1021_CR9","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/jgh.15783","volume":"37","author":"BH Yuan","year":"2022","unstructured":"Yuan, B. H. et al. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis. J. Gastroenterol. Hepatol. 37, 782\u2013794 (2022).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1021_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","volume":"152","author":"P Nahon","year":"2017","unstructured":"Nahon, P. et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 152, 142\u2013156.e2 (2017).","journal-title":"Gastroenterology"},{"key":"1021_CR11","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1002\/hep.30988","volume":"71","author":"H Dang","year":"2020","unstructured":"Dang, H. et al. Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both East and West. Hepatology 71, 1910\u20131922 (2020).","journal-title":"Hepatology"},{"key":"1021_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang, D. Q., El-Serag, H. B. & Loomba, R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 18, 223\u2013238 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1021_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41575-022-00688-6","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang, D. Q., Mathurin, P., Cortez-Pinto, H. & Loomba, R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat. Rev. Gastroenterol. Hepatol. 20, 37\u201349 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1021_CR14","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1007\/s12072-023-10503-2","volume":"17","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Contribution of alcohol use to the global burden of cirrhosis and liver cancer from 1990 to 2019 and projections to 2044. Hepatol. Int. 17, 1028\u20131044 (2023).","journal-title":"Hepatol. Int."},{"key":"1021_CR15","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/S0140-6736(18)32744-2","volume":"393","author":"J Manthey","year":"2019","unstructured":"Manthey, J. et al. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet 393, 2493\u20132502 (2019).","journal-title":"Lancet"},{"key":"1021_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"WK Chan","year":"2023","unstructured":"Chan, W. K. et al. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J. Obes. Metab. Syndr. 32, 197\u2013213 (2023).","journal-title":"J. Obes. Metab. Syndr."},{"key":"1021_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/joim.13545","volume":"292","author":"YH Yeo","year":"2022","unstructured":"Yeo, Y. H., Zou, B., Cheung, R. & Nguyen, M. H. Increased mortality of patients with alcohol-related liver diseases during the COVID-19 pandemic in the United States. J. Intern. Med. 292, 837\u2013839 (2022).","journal-title":"J. Intern. Med."},{"key":"1021_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279442","volume":"18","author":"HM Mamudu","year":"2023","unstructured":"Mamudu, H. M. et al. The prevalence of metabolic conditions before and during the COVID-19 pandemic and its association with health and sociodemographic factors. PLoS ONE 18, e0279442 (2023).","journal-title":"PLoS ONE"},{"key":"1021_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/aid.2020.0301","volume":"37","author":"L Sowah","year":"2021","unstructured":"Sowah, L. & Chiou, C. Impact of coronavirus disease 2019 pandemic on viral hepatitis elimination: what is the price. AIDS Res. Hum. Retroviruses 37, 585\u2013588 (2021).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"1021_CR20","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3390\/jcm11041126","volume":"11","author":"SP Kaur","year":"2022","unstructured":"Kaur, S. P. et al. Hepatocellular carcinoma in hepatitis B virus-infected patients and the role of hepatitis B surface antigen (HBsAg). J. Clin. Med. 11, 1123 (2022).","journal-title":"J. Clin. Med."},{"key":"1021_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","volume":"147","author":"CY Wu","year":"2014","unstructured":"Wu, C. Y. et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology 147, 143\u2013151.e5 (2014).","journal-title":"Gastroenterology"},{"key":"1021_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.26180","volume":"58","author":"T Hosaka","year":"2013","unstructured":"Hosaka, T. et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58, 98\u2013107 (2013).","journal-title":"Hepatology"},{"key":"1021_CR23","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin, P. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381, 468\u2013475 (2013).","journal-title":"Lancet"},{"key":"1021_CR24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","volume":"156","author":"YH Yeo","year":"2019","unstructured":"Yeo, Y. H. et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology 156, 635\u2013646.e9 (2019).","journal-title":"Gastroenterology"},{"key":"1021_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","volume":"70","author":"TC Yip","year":"2019","unstructured":"Yip, T. C. et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J. Hepatol. 70, 361\u2013370 (2019).","journal-title":"J. Hepatol."},{"key":"1021_CR26","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1016\/j.cgh.2021.04.031","volume":"20","author":"SG Lim","year":"2022","unstructured":"Lim, S. G. et al. Switching to or add-on peginterferon in patients on nucleos(t)ide analogues for chronic hepatitis B: the SWAP RCT. Clin. Gastroenterol. Hepatol. 20, e228\u2013e250 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1021_CR27","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.cgh.2023.02.032","volume":"21","author":"JJ Feld","year":"2023","unstructured":"Feld, J. J., Lok, A. S. & Zoulim, F. New perspectives on development of curative strategies for chronic hepatitis B. Clin. Gastroenterol. Hepatol. 21, 2040\u20132050 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1021_CR28","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1136\/gutjnl-2022-328041","volume":"72","author":"HLA Janssen","year":"2023","unstructured":"Janssen, H. L. A. et al. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection. Gut 72, 1385\u20131398 (2023).","journal-title":"Gut"},{"key":"1021_CR29","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jhep.2022.05.031","volume":"77","author":"MF Yuen","year":"2022","unstructured":"Yuen, M. F. et al. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. J. Hepatol. 77, 967\u2013977 (2022).","journal-title":"J. Hepatol."},{"key":"1021_CR30","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","volume":"387","author":"MF Yuen","year":"2022","unstructured":"Yuen, M. F. et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N. Engl. J. Med. 387, 1957\u20131968 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1021_CR31","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1053\/j.gastro.2016.05.048","volume":"151","author":"MH Chang","year":"2016","unstructured":"Chang, M. H. et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology 151, 472\u2013480.e1 (2016).","journal-title":"Gastroenterology"},{"key":"1021_CR32","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/apt.17120","volume":"56","author":"GL Wong","year":"2022","unstructured":"Wong, G. L. et al. Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 56, 869\u2013877 (2022).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1021_CR33","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.3748\/wjg.v28.i31.4249","volume":"28","author":"FA Di Lello","year":"2022","unstructured":"Di Lello, F. A., Martinez, A. P. & Flichman, D. M. Insights into induction of the immune response by the hepatitis B vaccine. World J. Gastroenterol. 28, 4249\u20134262 (2022).","journal-title":"World J. Gastroenterol."},{"key":"1021_CR34","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/hep.32758","volume":"77","author":"DJH Tan","year":"2023","unstructured":"Tan, D. J. H. et al. Global burden of liver cancer in males and females: changing etiological basis and the growing contribution of NASH. Hepatology 77, 1150\u20131163 (2023).","journal-title":"Hepatology"},{"key":"1021_CR35","doi-asserted-by":"publisher","first-page":"6435","DOI":"10.4049\/jimmunol.181.9.6435","volume":"181","author":"M W\u00f6lfl","year":"2008","unstructured":"W\u00f6lfl, M. et al. Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. J. Immunol. 181, 6435\u20136446 (2008).","journal-title":"J. Immunol."},{"key":"1021_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers\u00a07, 6 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1021_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/srep22487","volume":"6","author":"P Chusri","year":"2016","unstructured":"Chusri, P. et al. HCV induces transforming growth factor \u03b21 through activation of endoplasmic reticulum stress and the unfolded protein response. Sci. Rep. 6, 22487 (2016).","journal-title":"Sci. Rep."},{"key":"1021_CR38","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1038\/onc.2013.225","volume":"33","author":"H Quan","year":"2014","unstructured":"Quan, H. et al. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition. Oncogene 33, 2826\u20132835 (2014).","journal-title":"Oncogene"},{"key":"1021_CR39","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/hep.31060","volume":"71","author":"MG Ghany","year":"2020","unstructured":"Ghany, M. G. & Morgan, T. R. AASLD-IDSA Hepatitis C Guidance Panel Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology 71, 686\u2013721 (2020).","journal-title":"Hepatology"},{"key":"1021_CR40","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cgh.2009.10.026","volume":"8","author":"AK Singal","year":"2010","unstructured":"Singal, A. K. et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin. Gastroenterol. Hepatol. 8, 192\u2013199 (2010).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1021_CR41","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","volume":"393","author":"F Carrat","year":"2019","unstructured":"Carrat, F. et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 393, 1453\u20131464 (2019).","journal-title":"Lancet"},{"key":"1021_CR42","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1053\/j.gastro.2019.02.046","volume":"156","author":"AG Singal","year":"2019","unstructured":"Singal, A. G., Lim, J. K. & Kanwal, F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review. Gastroenterology 156, 2149\u20132157 (2019).","journal-title":"Gastroenterology"},{"key":"1021_CR43","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jhep.2020.02.022","volume":"73","author":"AA Butt","year":"2020","unstructured":"Butt, A. A. et al. Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: an ERCHIVES study. J. Hepatol. 73, 277\u2013284 (2020).","journal-title":"J. Hepatol."},{"key":"1021_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03272-1","volume":"12","author":"HW Yoo","year":"2022","unstructured":"Yoo, H. W. et al. Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents. Sci. Rep. 12, 193 (2022).","journal-title":"Sci. Rep."},{"key":"1021_CR45","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/apt.17802","volume":"59","author":"P Vutien","year":"2024","unstructured":"Vutien, P. et al. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication. Aliment. Pharmacol. Ther. 59, 361\u2013371 (2024).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1021_CR46","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1053\/j.gastro.2019.02.038","volume":"156","author":"N Hamdane","year":"2019","unstructured":"Hamdane, N. et al. HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response. Gastroenterology 156, 2313\u20132329.e7 (2019).","journal-title":"Gastroenterology"},{"key":"1021_CR47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","volume":"74","author":"S Blach","year":"2021","unstructured":"Blach, S. et al. Impact of COVID-19 on global HCV elimination efforts. J. Hepatol. 74, 31\u201336 (2021).","journal-title":"J. Hepatol."},{"key":"1021_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/srep33743","volume":"6","author":"YY Zhou","year":"2016","unstructured":"Zhou, Y. Y. et al. Systematic review with network meta-analysis: antidiabetic medication and risk of hepatocellular carcinoma. Sci. Rep. 6, 33743 (2016).","journal-title":"Sci. Rep."},{"key":"1021_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/JHC.S274933","volume":"8","author":"T Shi","year":"2021","unstructured":"Shi, T., Kobara, H., Oura, K. & Masaki, T. Mechanisms underlying hepatocellular carcinoma progression in patients with type 2 diabetes. J. Hepatocell. Carcinoma 8, 45\u201355 (2021).","journal-title":"J. Hepatocell. Carcinoma"},{"key":"1021_CR50","doi-asserted-by":"publisher","first-page":"154780","DOI":"10.1016\/j.metabol.2021.154780","volume":"120","author":"A Arvind","year":"2021","unstructured":"Arvind, A. et al. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: a meta-analysis. Metabolism 120, 154780 (2021).","journal-title":"Metabolism"},{"key":"1021_CR51","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jhep.2022.09.019","volume":"78","author":"PC Tsai","year":"2023","unstructured":"Tsai, P. C. et al. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. J. Hepatol. 78, 281\u2013292 (2023).","journal-title":"J. Hepatol."},{"key":"1021_CR52","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.aohep.2019.10.005","volume":"19","author":"V Cunha","year":"2020","unstructured":"Cunha, V., Cotrim, H. P., Rocha, R., Carvalho, K. & Lins-Kusterer, L. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: a systematic review. Ann. Hepatol. 19, 232\u2013237 (2020).","journal-title":"Ann. Hepatol."},{"key":"1021_CR53","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1136\/gutjnl-2011-301708","volume":"62","author":"HP Chen","year":"2013","unstructured":"Chen, H. P. et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62, 606\u2013615 (2013).","journal-title":"Gut"},{"key":"1021_CR54","doi-asserted-by":"publisher","first-page":"1327814","DOI":"10.3389\/fnut.2023.1327814","volume":"10","author":"G Ruan","year":"2023","unstructured":"Ruan, G. et al. Metformin: update on mechanisms of action on liver diseases. Front. Nutr. 10, 1327814 (2023).","journal-title":"Front. Nutr."},{"key":"1021_CR55","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/nm.3372","volume":"19","author":"MD Fullerton","year":"2013","unstructured":"Fullerton, M. D. et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat. Med. 19, 1649\u20131654 (2013).","journal-title":"Nat. Med."},{"key":"1021_CR56","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.3390\/ijms22073566","volume":"22","author":"CB Lee","year":"2021","unstructured":"Lee, C. B., Chae, S. U., Jo, S. J., Jerng, U. M. & Bae, S. K. The relationship between the gut microbiome and metformin as a key for treating type 2 diabetes mellitus. Int. J. Mol. Sci. 22, 3566 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1021_CR57","doi-asserted-by":"publisher","first-page":"8436","DOI":"10.1074\/jbc.M116.769380","volume":"292","author":"T Horiuchi","year":"2017","unstructured":"Horiuchi, T. et al. Metformin directly binds the alarmin HMGB1 and inhibits its proinflammatory activity. J. Biol. Chem. 292, 8436\u20138446 (2017).","journal-title":"J. Biol. Chem."},{"key":"1021_CR58","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1530\/JOE-21-0194","volume":"251","author":"R Kristofi","year":"2021","unstructured":"Kristofi, R. & Eriksson, J. W. Metformin as an anti-inflammatory agent: a short review. J. Endocrinol. 251, R11\u2013R22 (2021).","journal-title":"J. Endocrinol."},{"key":"1021_CR59","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.cmet.2018.01.013","volume":"27","author":"PV Bauer","year":"2018","unstructured":"Bauer, P. V. et al. Lactobacillus gasseri in the upper small intestine impacts an ACSL3-dependent fatty acid-sensing pathway regulating whole-body glucose homeostasis. Cell Metab. 27, 572\u2013587.e6 (2018).","journal-title":"Cell Metab."},{"key":"1021_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1465","volume":"13","author":"W He","year":"2023","unstructured":"He, W. et al. Metformin reduces hepatocarcinogenesis by inducing downregulation of Cyp26a1 and CD8+ T cells. Clin. Transl. Med. 13, e1465 (2023).","journal-title":"Clin. Transl. Med."},{"key":"1021_CR61","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/19490976.2017.1405209","volume":"9","author":"H Lee","year":"2018","unstructured":"Lee, H. et al. Modulation of the gut microbiota by metformin improves metabolic profiles in aged obese mice. Gut Microbes 9, 155\u2013165 (2018).","journal-title":"Gut Microbes"},{"key":"1021_CR62","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/dom.12826","volume":"19","author":"D Preiss","year":"2017","unstructured":"Preiss, D. et al. Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. Diabetes Obes. Metab. 19, 356\u2013363 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"1021_CR63","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.cell.2019.08.003","volume":"178","author":"R Pryor","year":"2019","unstructured":"Pryor, R. et al. Host-microbe-drug-nutrient screen identifies bacterial effectors of metformin therapy. Cell 178, 1299\u20131312.e29 (2019).","journal-title":"Cell"},{"key":"1021_CR64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2211933120","volume":"120","author":"N Tobar","year":"2023","unstructured":"Tobar, N. et al. Metformin acts in the gut and induces gut-liver crosstalk. Proc. Natl Acad. Sci. USA 120, e2211933120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1021_CR65","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","volume":"184","author":"F Kanwal","year":"2024","unstructured":"Kanwal, F. GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease. JAMA Intern. Med. 184, 1314\u20131323 (2024).","journal-title":"JAMA Intern. Med."},{"key":"1021_CR66","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/hep.23569","volume":"51","author":"NA Gupta","year":"2010","unstructured":"Gupta, N. A. et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51, 1584\u20131592 (2010).","journal-title":"Hepatology"},{"key":"1021_CR67","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1478-3231.2011.02462.x","volume":"31","author":"G Svegliati-Baroni","year":"2011","unstructured":"Svegliati-Baroni, G. et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 31, 1285\u20131297 (2011).","journal-title":"Liver Int."},{"key":"1021_CR68","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/17474124.2023.2172397","volume":"17","author":"Y Gu","year":"2023","unstructured":"Gu, Y. et al. Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials. Expert. Rev. Gastroenterol. Hepatol. 17, 273\u2013282 (2023).","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"1021_CR69","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1016\/j.apsb.2021.12.016","volume":"12","author":"N Song","year":"2022","unstructured":"Song, N. et al. Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis. Acta Pharm. Sin. B 12, 2443\u20132461 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"1021_CR70","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.3390\/ijms21165722","volume":"21","author":"M Kojima","year":"2020","unstructured":"Kojima, M. et al. Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis. Int. J. Mol. Sci. 21, 5722 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1021_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50328-5","volume":"13","author":"HH Hansen","year":"2023","unstructured":"Hansen, H. H. et al. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis. Sci. Rep. 13, 23056 (2023).","journal-title":"Sci. Rep."},{"key":"1021_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2016.85","volume":"6","author":"T Feng","year":"2017","unstructured":"Feng, T. et al. Hepatocyte-specific Smad7 deletion accelerates DEN-induced HCC via activation of STAT3 signaling in mice. Oncogenesis 6, e294 (2017).","journal-title":"Oncogenesis"},{"key":"1021_CR73","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1038\/onc.2017.38","volume":"36","author":"M Zhou","year":"2017","unstructured":"Zhou, M. et al. The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis. Oncogene 36, 4135\u20134149 (2017).","journal-title":"Oncogene"},{"key":"1021_CR74","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1097\/HEP.0000000000000712","volume":"79","author":"A Engstr\u00f6m","year":"2023","unstructured":"Engstr\u00f6m, A. et al. Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: a Scandinavian cohort study. Hepatology 79, 1401\u20131411 (2023).","journal-title":"Hepatology"},{"key":"1021_CR75","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/joim.13751","volume":"295","author":"CT Yang","year":"2024","unstructured":"Yang, C. T. et al. Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: a nationwide cohort study using target trial emulation framework. J. Intern. Med. 295, 357\u2013368 (2024).","journal-title":"J. Intern. Med."},{"key":"1021_CR76","doi-asserted-by":"publisher","first-page":"110539","DOI":"10.1016\/j.mce.2019.110539","volume":"498","author":"TI Petito-da-Silva","year":"2019","unstructured":"Petito-da-Silva, T. I., Souza-Mello, V. & Barbosa-da-Silva, S. Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress. Mol. Cell Endocrinol. 498, 110539 (2019).","journal-title":"Mol. Cell Endocrinol."},{"key":"1021_CR77","doi-asserted-by":"publisher","first-page":"107492","DOI":"10.1016\/j.intimp.2021.107492","volume":"94","author":"Z Meng","year":"2021","unstructured":"Meng, Z. et al. The SGLT2 inhibitor empagliflozin negatively regulates IL-17\/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK\/mTOR\/autophagy pathway. Int. Immunopharmacol. 94, 107492 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"1021_CR78","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/ijms22020818","volume":"22","author":"N Nasiri-Ansari","year":"2021","unstructured":"Nasiri-Ansari, N. et al. Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE\u2212\/\u2212 mice by activating autophagy and reducing ER stress and apoptosis. Int. J. Mol. Sci. 22, 818 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1021_CR79","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.3390\/ijms20205237","volume":"20","author":"T Jojima","year":"2019","unstructured":"Jojima, T. et al. The SGLT2 inhibitor canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma. Int. J. Mol. Sci. 20, 5237 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1021_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232283","volume":"15","author":"D Nakano","year":"2020","unstructured":"Nakano, D. et al. Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). PLoS ONE 15, e0232283 (2020).","journal-title":"PLoS ONE"},{"key":"1021_CR81","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/HEP.0000000000000855","volume":"80","author":"KS Cheung","year":"2024","unstructured":"Cheung, K. S. et al. Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Hepatology 80, 916\u2013927 (2024).","journal-title":"Hepatology"},{"key":"1021_CR82","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","volume":"84","author":"H Jang","year":"2024","unstructured":"Jang, H. et al. Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease. JAMA Intern. Med. 84, 375\u2013383 (2024).","journal-title":"JAMA Intern. Med."},{"key":"1021_CR83","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","volume":"16","author":"F Bril","year":"2018","unstructured":"Bril, F. et al. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes. Clin. Gastroenterol. Hepatol. 16, 558\u2013566.e2 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1021_CR84","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11605-018-4004-6","volume":"23","author":"S Li","year":"2019","unstructured":"Li, S. et al. Pioglitazone reduces hepatocellular carcinoma development in two rodent models of cirrhosis. J. Gastrointest. Surg. 23, 101\u2013111 (2019).","journal-title":"J. Gastrointest. Surg."},{"key":"1021_CR85","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2174\/1381612826666200122124116","volume":"26","author":"LA Biondo","year":"2020","unstructured":"Biondo, L. A., Teixeira, A. A. S., de O. S. Ferreira, K. C. & Neto, J. C. R. Pharmacological strategies for insulin sensitivity in obesity and cancer: thiazolidinediones and metformin. Curr. Pharm. Des. 26, 932\u2013945 (2020).","journal-title":"Curr. Pharm. Des."},{"key":"1021_CR86","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1245\/s10434-007-9698-8","volume":"15","author":"K Hiwatashi","year":"2008","unstructured":"Hiwatashi, K. et al. A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC. Ann. Surg. Oncol. 15, 923\u2013933 (2008).","journal-title":"Ann. Surg. Oncol."},{"key":"1021_CR87","doi-asserted-by":"publisher","first-page":"22527","DOI":"10.3390\/ijms160922527","volume":"16","author":"X Wang","year":"2015","unstructured":"Wang, X. et al. The role of HMGB1 signaling pathway in the development and progression of hepatocellular carcinoma: a review. Int. J. Mol. Sci. 16, 22527\u201322540 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"1021_CR88","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/mc.22231","volume":"54","author":"Y Yang","year":"2015","unstructured":"Yang, Y. et al. Pioglitazone, a PPAR\u03b3 agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling. Mol. Carcinog. 54, 1584\u20131595 (2015).","journal-title":"Mol. Carcinog."},{"key":"1021_CR89","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","volume":"330","author":"M Sodhi","year":"2023","unstructured":"Sodhi, M., Rezaeianzadeh, R., Kezouh, A. & Etminan, M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 330, 1795\u20131797 (2023).","journal-title":"JAMA"},{"key":"1021_CR90","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.2337\/dc22-0712","volume":"45","author":"R Pradhan","year":"2022","unstructured":"Pradhan, R., Yin, H., Yu, O. H. Y. & Azoulay, L. Incretin-based drugs and the risk of acute liver injury among patients with type 2 diabetes. Diabetes Care 45, 2289\u20132298 (2022).","journal-title":"Diabetes Care"},{"key":"1021_CR91","doi-asserted-by":"publisher","first-page":"1010693","DOI":"10.3389\/fcvm.2022.1010693","volume":"9","author":"A Mascolo","year":"2022","unstructured":"Mascolo, A. et al. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: a brief summary. Front. Cardiovasc. Med. 9, 1010693 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"1021_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01965-0","volume":"7","author":"W Wang","year":"2017","unstructured":"Wang, W. et al. Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis. Sci. Rep. 7, 1717 (2017).","journal-title":"Sci. Rep."},{"key":"1021_CR93","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1001\/jama.298.22.2634","volume":"298","author":"L Lipscombe","year":"2007","unstructured":"Lipscombe, L. et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298, 2634\u20132643 (2007).","journal-title":"JAMA"},{"key":"1021_CR94","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett, D. K. et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140, e596\u2013e646 (2019).","journal-title":"Circulation"},{"key":"1021_CR95","doi-asserted-by":"publisher","first-page":"626971","DOI":"10.3389\/fonc.2021.626971","volume":"11","author":"B Guerra","year":"2021","unstructured":"Guerra, B. et al. The mevalonate pathway, a metabolic target in cancer therapy. Front. Oncol. 11, 626971 (2021).","journal-title":"Front. Oncol."},{"key":"1021_CR96","doi-asserted-by":"publisher","first-page":"172704","DOI":"10.1016\/j.ejphar.2019.172704","volume":"863","author":"N Mohammadkhani","year":"2019","unstructured":"Mohammadkhani, N. et al. Statins: complex outcomes but increasingly helpful treatment options for patients. Eur. J. Pharmacol. 863, 172704 (2019).","journal-title":"Eur. J. Pharmacol."},{"key":"1021_CR97","doi-asserted-by":"publisher","first-page":"165968","DOI":"10.1016\/j.bbadis.2020.165968","volume":"1866","author":"M Ahmadi","year":"2020","unstructured":"Ahmadi, M. et al. Pleiotropic effects of statins: a focus on cancer. Biochim. Biophys. Acta Mol. Basis Dis. 1866, 165968 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"1021_CR98","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.jhep.2005.04.010","volume":"43","author":"AP Sutter","year":"2005","unstructured":"Sutter, A. P. et al. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J. Hepatol. 43, 808\u2013816 (2005).","journal-title":"J. Hepatol."},{"key":"1021_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.472","volume":"8","author":"ST Wang","year":"2017","unstructured":"Wang, S. T., Ho, H. J., Lin, J. T., Shieh, J. J. & Wu, C. Y. Simvastatin-induced cell cycle arrest through inhibition of STAT3\/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Cell Death Dis. 8, e2626 (2017).","journal-title":"Cell Death Dis."},{"key":"1021_CR100","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3892\/or.2012.1860","volume":"28","author":"J Kah","year":"2012","unstructured":"Kah, J. et al. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol. Rep. 28, 1077\u20131083 (2012).","journal-title":"Oncol. Rep."},{"key":"1021_CR101","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/hep.27835","volume":"62","author":"AA Butt","year":"2015","unstructured":"Butt, A. A. et al. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: results from ERCHIVES. Hepatology 62, 365\u2013374 (2015).","journal-title":"Hepatology"},{"key":"1021_CR102","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/hep.28506","volume":"64","author":"TG Simon","year":"2016","unstructured":"Simon, T. G., Bonilla, H., Yan, P., Chung, R. T. & Butt, A. A. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES. Hepatology 64, 47\u201357 (2016).","journal-title":"Hepatology"},{"key":"1021_CR103","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.cgh.2022.01.057","volume":"21","author":"B Zou","year":"2023","unstructured":"Zou, B., Odden, M. C. & Nguyen, M. H. Statin use and reduced hepatocellular carcinoma risk in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 21, 435\u2013444.e6 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1021_CR104","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.20222","volume":"6","author":"MS Vell","year":"2023","unstructured":"Vell, M. S. et al. Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality. JAMA Netw. Open\u00a06, e2320222 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1021_CR105","doi-asserted-by":"publisher","first-page":"21753","DOI":"10.18632\/oncotarget.7832","volume":"7","author":"YY Zhou","year":"2016","unstructured":"Zhou, Y. Y. et al. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma. Oncotarget 7, 21753\u201321762 (2016).","journal-title":"Oncotarget"},{"key":"1021_CR106","doi-asserted-by":"publisher","first-page":"318","DOI":"10.7326\/M18-2753","volume":"171","author":"TG Simon","year":"2019","unstructured":"Simon, T. G. et al. Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a nationwide Swedish population. Ann. Intern. Med. 171, 318\u2013327 (2019).","journal-title":"Ann. Intern. Med."},{"key":"1021_CR107","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000332","volume":"7","author":"TM Kronborg","year":"2023","unstructured":"Kronborg, T. M. et al. Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial. Hepatol. Commun. 7, e0332 (2023).","journal-title":"Hepatol. Commun."},{"key":"1021_CR108","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","volume":"8","author":"H Bays","year":"2014","unstructured":"Bays, H., Cohen, D. E., Chalasani, N. & Harrison, S. A. The National Lipid Association\u2019s Statin Safety Task Force An assessment by the Statin Liver Safety Task Force: 2014 update. J. Clin. Lipidol. 8, S47\u2013S57 (2014).","journal-title":"J. Clin. Lipidol."},{"key":"1021_CR109","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/1940-6207.CAPR-16-0241","volume":"10","author":"LM Lichtenberger","year":"2017","unstructured":"Lichtenberger, L. M. et al. Unlocking aspirin\u2019s chemopreventive activity: role of irreversibly inhibiting platelet cyclooxygenase-1. Cancer Prev. Res. 10, 142\u2013152 (2017).","journal-title":"Cancer Prev. Res."},{"key":"1021_CR110","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10555-017-9675-z","volume":"36","author":"A Ornelas","year":"2017","unstructured":"Ornelas, A. et al. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. 36, 289\u2013303 (2017).","journal-title":"Cancer Metastasis Rev."},{"key":"1021_CR111","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/hep.22215","volume":"47","author":"K Trujillo-Murillo","year":"2008","unstructured":"Trujillo-Murillo, K. et al. Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. Hepatology 47, 1462\u20131472 (2008).","journal-title":"Hepatology"},{"key":"1021_CR112","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","volume":"25","author":"M Malehmir","year":"2019","unstructured":"Malehmir, M. et al. Platelet GPIb\u03b1 is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat. Med. 25, 641\u2013655 (2019).","journal-title":"Nat. Med."},{"key":"1021_CR113","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.18632\/aging.103002","volume":"12","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Aspirin alleviates hepatic fibrosis by suppressing hepatic stellate cells activation via the TLR4\/NF-\u03baB pathway. Aging 12, 6058\u20136066 (2020).","journal-title":"Aging"},{"key":"1021_CR114","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","volume":"382","author":"TG Simon","year":"2020","unstructured":"Simon, T. G. et al. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N. Engl. J. Med. 382, 1018\u20131028 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1021_CR115","doi-asserted-by":"publisher","first-page":"102065","DOI":"10.1016\/j.eclinm.2023.102065","volume":"61","author":"TY Lee","year":"2023","unstructured":"Lee, T. Y. et al. Daily aspirin associated with a reduced risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a population-based cohort study. EClinicalMedicine 61, 102065 (2023).","journal-title":"EClinicalMedicine"},{"key":"1021_CR116","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019008","volume":"99","author":"S Shin","year":"2020","unstructured":"Shin, S. et al. Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis. Medicine 99, e19008 (2020).","journal-title":"Medicine"},{"key":"1021_CR117","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/apt.17371","volume":"57","author":"RW Zeng","year":"2023","unstructured":"Zeng, R. W. et al. Meta-analysis: chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. Aliment. Pharmacol. Ther. 57, 600\u2013609 (2023).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1021_CR118","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1159\/000343852","volume":"2","author":"G Ramakrishna","year":"2013","unstructured":"Ramakrishna, G. et al. From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer 2, 367\u2013383 (2013).","journal-title":"Liver Cancer"},{"key":"1021_CR119","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal, A. J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N. Engl. J. Med. 385, 1559\u20131569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1021_CR120","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14, 397\u2013411 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1021_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04377-1","volume":"12","author":"V De Smet","year":"2021","unstructured":"De Smet, V. et al. Initiation of hepatic stellate cell activation extends into chronic liver disease. Cell Death Dis. 12, 1110 (2021).","journal-title":"Cell Death Dis."},{"key":"1021_CR122","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00011-010-0306-1","volume":"60","author":"B Renga","year":"2011","unstructured":"Renga, B. et al. SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-\u03b3 by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts. Inflamm. Res. 60, 577\u2013587 (2011).","journal-title":"Inflamm. Res."},{"key":"1021_CR123","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.phrs.2018.02.033","volume":"131","author":"A Carino","year":"2018","unstructured":"Carino, A. et al. Disruption of TFG\u03b2-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand. Pharmacol. Res. 131, 17\u201331 (2018).","journal-title":"Pharmacol. Res."},{"key":"1021_CR124","doi-asserted-by":"publisher","first-page":"105911","DOI":"10.1016\/j.intimp.2019.105911","volume":"77","author":"YY Fan","year":"2019","unstructured":"Fan, Y. Y. et al. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3. Int. Immunopharmacol. 77, 105911 (2019).","journal-title":"Int. Immunopharmacol."},{"key":"1021_CR125","first-page":"501","volume":"19","author":"A Mullard","year":"2020","unstructured":"Mullard, A. FDA rejects NASH drug. Nat. Rev. Drug. Discov. 19, 501 (2020).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1021_CR126","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nbt1114-1069","volume":"32","author":"M Ratner","year":"2014","unstructured":"Ratner, M. Landmark approvals in idiopathic pulmonary fibrosis. Nat. Biotechnol. 32, 1069\u20131070 (2014).","journal-title":"Nat. Biotechnol."},{"key":"1021_CR127","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3390\/ijms222111360","volume":"22","author":"JA Silva-Gomez","year":"2021","unstructured":"Silva-Gomez, J. A. et al. Hepatocarcinogenesis prevention by pirfenidone is PPAR\u03b3 mediated and involves modification of nuclear NF-kB p65\/p50 ratio. Int J. Mol. Sci. 22, 1360 (2021).","journal-title":"Int J. Mol. Sci."},{"key":"1021_CR128","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.12659\/MSM.907891","volume":"23","author":"WJ Zou","year":"2017","unstructured":"Zou, W. J. et al. Pirfenidone inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells by inhibiting the Wnt\/\u03b2-catenin signaling pathway. Med. Sci. Monit. 23, 6107\u20136113 (2017).","journal-title":"Med. Sci. Monit."},{"key":"1021_CR129","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03080-9","volume":"23","author":"B Hassani","year":"2023","unstructured":"Hassani, B., Attar, Z. & Firouzabadi, N. The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies. Cancer Cell Int. 23, 254 (2023).","journal-title":"Cancer Cell Int."},{"key":"1021_CR130","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1159\/000069792","volume":"23","author":"H Yoshiji","year":"2002","unstructured":"Yoshiji, H., Kuriyama, S. & Fukui, H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol. 23, 348\u2013356 (2002).","journal-title":"Tumour Biol."},{"key":"1021_CR131","first-page":"330","volume":"8","author":"L Fala","year":"2015","unstructured":"Fala, L. Entresto (sacubitril\/valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure. Am. Health Drug. Benefits 8, 330\u2013334 (2015).","journal-title":"Am. Health Drug. Benefits"},{"key":"1021_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25468-9","volume":"12","author":"E Crouchet","year":"2021","unstructured":"Crouchet, E. et al. A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. Nat. Commun. 12, 5525 (2021).","journal-title":"Nat. Commun."},{"key":"1021_CR133","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159254","volume":"7","author":"E Crouchet","year":"2022","unstructured":"Crouchet, E. et al. Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation. JCI Insight 7, e159254 (2022).","journal-title":"JCI Insight"},{"key":"1021_CR134","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.toxlet.2018.05.036","volume":"295","author":"S Saber","year":"2018","unstructured":"Saber, S. et al. Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B. Toxicol. Lett. 295, 32\u201340 (2018).","journal-title":"Toxicol. Lett."},{"key":"1021_CR135","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1053\/jhep.2001.28231","volume":"34","author":"H Yoshiji","year":"2001","unstructured":"Yoshiji, H. et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34, 745\u2013750 (2001).","journal-title":"Hepatology"},{"key":"1021_CR136","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1111\/j.1440-1746.2006.04663.x","volume":"22","author":"H Yoshiji","year":"2007","unstructured":"Yoshiji, H., Kuriyama, S. & Fukui, H. Blockade of renin-angiotensin system in antifibrotic therapy. J. Gastroenterol. Hepatol. 22, S93\u2013S95 (2007).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1021_CR137","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1139\/cjpp-2017-0728","volume":"96","author":"S Saber","year":"2018","unstructured":"Saber, S., Mahmoud, A. A. A., Helal, N. S., El-Ahwany, E. & Abdelghany, R. H. Renin-angiotensin system inhibition ameliorates CCl4-induced liver fibrosis in mice through the inactivation of nuclear transcription factor kappa B. Can. J. Physiol. Pharmacol. 96, 569\u2013576 (2018).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"1021_CR138","first-page":"1073","volume":"7","author":"H Yoshiji","year":"2001","unstructured":"Yoshiji, H. et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res. 7, 1073\u20131078 (2001).","journal-title":"Clin. Cancer Res."},{"key":"1021_CR139","first-page":"1227","volume":"20","author":"H Yoshiji","year":"2002","unstructured":"Yoshiji, H. et al. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int. J. Oncol. 20, 1227\u20131231 (2002).","journal-title":"Int. J. Oncol."},{"key":"1021_CR140","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/hep4.1104","volume":"1","author":"T Namisaki","year":"2017","unstructured":"Namisaki, T. et al. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. Hepatol. Commun. 1, 928\u2013945 (2017).","journal-title":"Hepatol. Commun."},{"key":"1021_CR141","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3748\/wjg.v25.i20.2524","volume":"25","author":"M Barone","year":"2019","unstructured":"Barone, M., Viggiani, M. T., Losurdo, G., Principi, M. & Leo, A. D. Systematic review: renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma. World J. Gastroenterol. 25, 2524\u20132538 (2019).","journal-title":"World J. Gastroenterol."},{"key":"1021_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4292-y","volume":"18","author":"CM Ho","year":"2018","unstructured":"Ho, C. M. et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study. BMC Cancer 18, 401 (2018).","journal-title":"BMC Cancer"},{"key":"1021_CR143","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cgh.2023.07.009","volume":"22","author":"H Elhence","year":"2024","unstructured":"Elhence, H., Dodge, J. L. & Lee, B. P. Association of renin-angiotensin system inhibition with liver-related events and mortality in compensated cirrhosis. Clin. Gastroenterol. Hepatol. 22, 315\u2013323.e7 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1021_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-446","volume":"11","author":"GA Heckley","year":"2011","unstructured":"Heckley, G. A., Jarl, J., Asamoah, B. O. & U, G. G. How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature. BMC Cancer 11, 446 (2011).","journal-title":"BMC Cancer"},{"key":"1021_CR145","doi-asserted-by":"publisher","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","volume":"119","author":"LL Jophlin","year":"2024","unstructured":"Jophlin, L. L. et al. ACG clinical guideline: alcohol-associated liver disease. Am. J. Gastroenterol. 119, 30\u201354 (2024).","journal-title":"Am. J. Gastroenterol."},{"key":"1021_CR146","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.13014","volume":"5","author":"AGL Vannier","year":"2022","unstructured":"Vannier, A. G. L. et al. Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder. JAMA Netw. Open. 5, e2213014 (2022).","journal-title":"JAMA Netw. Open."},{"key":"1021_CR147","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.14309\/ajg.0000000000001399","volume":"116","author":"M Rodriguez","year":"2021","unstructured":"Rodriguez, M. et al. Impact of alcohol abstinence on the risk of hepatocellular carcinoma in patients with alcohol-related liver cirrhosis. Am. J. Gastroenterol. 116, 2390\u20132398 (2021).","journal-title":"Am. J. Gastroenterol."},{"key":"1021_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48267-2","volume":"13","author":"F Quddos","year":"2023","unstructured":"Quddos, F. et al. Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity. Sci. Rep. 13, 20998 (2023).","journal-title":"Sci. Rep."},{"key":"1021_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48780-6","volume":"15","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat. Commun. 15, 4548 (2024).","journal-title":"Nat. Commun."},{"key":"1021_CR150","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013739","volume":"7","author":"OJ Kennedy","year":"2017","unstructured":"Kennedy, O. J. et al. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis. BMJ Open. 7, e013739 (2017).","journal-title":"BMJ Open."},{"key":"1021_CR151","first-page":"421","volume":"29","author":"A Bhurwal","year":"2020","unstructured":"Bhurwal, A. et al. Inverse association of coffee with liver cancer development: an updated systematic review and meta-analysis. J. Gastrointest. Liver Dis. 29, 421\u2013428 (2020).","journal-title":"J. Gastrointest. Liver Dis."},{"key":"1021_CR152","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41416-019-0465-y","volume":"120","author":"KT Tran","year":"2019","unstructured":"Tran, K. T., Coleman, H. G., McMenamin, \u00da. C. & Cardwell, C. R. Coffee consumption by type and risk of digestive cancer: a large prospective cohort study. Br. J. Cancer 120, 1059\u20131066 (2019).","journal-title":"Br. J. Cancer"},{"key":"1021_CR153","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/antiox11020379","volume":"11","author":"T Barr\u00e9","year":"2022","unstructured":"Barr\u00e9, T. et al. Metabolic disorders in patients with chronic hepatitis B virus infection: coffee as a panacea? (ANRS CO22 Hepather Cohort). Antioxidants 11, 379 (2022).","journal-title":"Antioxidants"},{"key":"1021_CR154","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/nu15010004","volume":"15","author":"M Coelho","year":"2022","unstructured":"Coelho, M. et al. Increased intake of both caffeine and non-caffeine coffee components is associated with reduced NAFLD severity in subjects with type 2 diabetes. Nutrients 15, 4 (2022).","journal-title":"Nutrients"},{"key":"1021_CR155","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1742-7843.2008.00231.x","volume":"102","author":"J Okano","year":"2008","unstructured":"Okano, J., Nagahara, T., Matsumoto, K. & Murawaki, Y. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK\/ERK\/EGFR signalling pathway. Basic. Clin. Pharmacol. Toxicol. 102, 543\u2013551 (2008).","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"1021_CR156","doi-asserted-by":"publisher","first-page":"1029491","DOI":"10.3389\/fonc.2022.1029491","volume":"12","author":"FS Fan","year":"2022","unstructured":"Fan, F. S. Coffee reduces the risk of hepatocellular carcinoma probably through inhibition of NLRP3 inflammasome activation by caffeine. Front. Oncol. 12, 1029491 (2022).","journal-title":"Front. Oncol."},{"key":"1021_CR157","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000516067","volume":"30","author":"EKJ Pauwels","year":"2021","unstructured":"Pauwels, E. K. J. & Volterrani, D. Coffee consumption and cancer risk: an assessment of the health implications based on recent knowledge. Med. Princ. Pract. 30, 401\u2013411 (2021).","journal-title":"Med. Princ. Pract."},{"key":"1021_CR158","doi-asserted-by":"publisher","first-page":"114124","DOI":"10.1016\/j.biopha.2022.114124","volume":"158","author":"P Peerapen","year":"2023","unstructured":"Peerapen, P., Chanthick, C. & Thongboonkerd, V. Quantitative proteomics reveals common and unique molecular mechanisms underlying beneficial effects of caffeine and trigonelline on human hepatocytes. Biomed. Pharmacother. 158, 114124 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"1021_CR159","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/jnci\/djz122","volume":"112","author":"E Loftfield","year":"2020","unstructured":"Loftfield, E. et al. Prospective investigation of serum metabolites, coffee drinking, liver cancer incidence, and liver disease mortality. J. Natl Cancer Inst. 112, 286\u2013294 (2020).","journal-title":"J. Natl Cancer Inst."},{"key":"1021_CR160","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.3748\/wjg.v25.i31.4300","volume":"25","author":"B Murray","year":"2019","unstructured":"Murray, B., Barbier-Torres, L., Fan, W., Mato, J. M. & Lu, S. C. Methionine adenosyltransferases in liver cancer. World J. Gastroenterol. 25, 4300\u20134319 (2019).","journal-title":"World J. Gastroenterol."},{"key":"1021_CR161","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.3390\/molecules25184237","volume":"25","author":"L Vergani","year":"2020","unstructured":"Vergani, L. et al. New perspectives of S-adenosylmethionine (SAMe) applications to attenuate fatty acid-induced steatosis and oxidative stress in hepatic and endothelial cells. Molecules 25, 4237 (2020).","journal-title":"Molecules"},{"key":"1021_CR162","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1158\/1940-6207.CAPR-15-0029","volume":"8","author":"TR Morgan","year":"2015","unstructured":"Morgan, T. R. et al. A phase II randomized, controlled trial of S-adenosylmethionine in reducing serum \u03b1-fetoprotein in patients with hepatitis C cirrhosis and elevated AFP. Cancer Prev. Res. 8, 864\u2013872 (2015).","journal-title":"Cancer Prev. Res."},{"key":"1021_CR163","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1158\/1055-9965.EPI-16-0747","volume":"26","author":"JD Yang","year":"2017","unstructured":"Yang, J. D. et al. Improved performance of serum alpha-fetoprotein for hepatocellular carcinoma diagnosis in HCV cirrhosis with normal alanine transaminase. Cancer Epidemiol. Biomark. Prev. 26, 1085\u20131092 (2017).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1021_CR164","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/jgh.15202","volume":"36","author":"L Chrysavgis","year":"2021","unstructured":"Chrysavgis, L., Papatheodoridi, A. M., Chatzigeorgiou, A. & Cholongitas, E. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 36, 893\u2013909 (2021).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1021_CR165","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1177\/1535370220987524","volume":"246","author":"H Lim","year":"2021","unstructured":"Lim, H., Lee, H. & Lim, Y. Effect of vitamin D3 supplementation on hepatic lipid dysregulation associated with autophagy regulatory AMPK\/Akt-mTOR signaling in type 2 diabetic mice. Exp. Biol. Med. 246, 1139\u20131147 (2021).","journal-title":"Exp. Biol. Med."},{"key":"1021_CR166","doi-asserted-by":"publisher","first-page":"106022","DOI":"10.1016\/j.jsbmb.2021.106022","volume":"215","author":"RL Goto","year":"2022","unstructured":"Goto, R. L. et al. Vitamin D3 supplementation alleviates chemically-induced cirrhosis-associated hepatocarcinogenesis. J. Steroid Biochem. Mol. Biol. 215, 106022 (2022).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"1021_CR167","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00508-016-1127-1","volume":"129","author":"R Paternostro","year":"2017","unstructured":"Paternostro, R. et al. Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. Wien. Klin. Wochenschr. 129, 8\u201315 (2017).","journal-title":"Wien. Klin. Wochenschr."},{"key":"1021_CR168","doi-asserted-by":"publisher","first-page":"k671","DOI":"10.1136\/bmj.k671","volume":"360","author":"S Budhathoki","year":"2018","unstructured":"Budhathoki, S. et al. Plasma 25-hydroxyvitamin D concentration and subsequent risk of total and site specific cancers in Japanese population: large case-cohort study within Japan Public Health Center-based Prospective Study cohort. BMJ 360, k671 (2018).","journal-title":"BMJ"},{"key":"1021_CR169","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.21037\/atm-20-1637","volume":"8","author":"H Liu","year":"2020","unstructured":"Liu, H. et al. Association of circulating 25-Hydroxyvitamin D and its related genetic variations with hepatocellular carcinoma incidence and survival. Ann. Transl. Med. 8, 1080 (2020).","journal-title":"Ann. Transl. Med."},{"key":"1021_CR170","first-page":"1119","volume":"12","author":"M Shimizu","year":"2012","unstructured":"Shimizu, M., Imai, K., Takai, K. & Moriwaki, H. Role of acyclic retinoid in the chemoprevention of hepatocellular carcinoma: basic aspects, clinical applications, and future prospects. Curr. Cancer Drug. Targets 12, 1119\u20131128 (2012).","journal-title":"Curr. Cancer Drug. Targets"},{"key":"1021_CR171","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1053\/j.gastro.2012.02.018","volume":"142","author":"N Sawada","year":"2012","unstructured":"Sawada, N. et al. Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology 142, 1468\u20131475 (2012).","journal-title":"Gastroenterology"},{"key":"1021_CR172","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1002\/ijc.29643","volume":"137","author":"T Duarte-Salles","year":"2015","unstructured":"Duarte-Salles, T. et al. Dietary fat, fat subtypes and hepatocellular carcinoma in a large European cohort. Int. J. Cancer 137, 2715\u20132728 (2015).","journal-title":"Int. J. Cancer"},{"key":"1021_CR173","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10552-014-0512-1","volume":"26","author":"M Gao","year":"2015","unstructured":"Gao, M. et al. Fish consumption and n-3 polyunsaturated fatty acids, and risk of hepatocellular carcinoma: systematic review and meta-analysis. Cancer Causes Control. 26, 367\u2013376 (2015).","journal-title":"Cancer Causes Control."},{"key":"1021_CR174","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1016\/j.cgh.2020.01.003","volume":"18","author":"W Yang","year":"2020","unstructured":"Yang, W. et al. High dietary intake of vegetable or polyunsaturated fats is associated with reduced risk of hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 18, 2775\u20132783.e11 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1021_CR175","doi-asserted-by":"publisher","first-page":"18191","DOI":"10.18632\/oncotarget.15304","volume":"8","author":"K Takegoshi","year":"2017","unstructured":"Takegoshi, K. et al. Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model. Oncotarget 8, 18191\u201318205 (2017).","journal-title":"Oncotarget"},{"key":"1021_CR176","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/ijc.20636","volume":"113","author":"B Chang","year":"2005","unstructured":"Chang, B., Nishikawa, M., Nishiguchi, S. & Inoue, M. L-carnitine inhibits hepatocarcinogenesis via protection of mitochondria. Int. J. Cancer 113, 719\u2013729 (2005).","journal-title":"Int. J. Cancer"},{"key":"1021_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/srep24399","volume":"6","author":"G Yang","year":"2016","unstructured":"Yang, G., Lee, H. E. & Lee, J. Y. A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet. Sci. Rep. 6, 24399 (2016).","journal-title":"Sci. Rep."},{"key":"1021_CR178","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/tox.23396","volume":"37","author":"W Wu","year":"2022","unstructured":"Wu, W. et al. Estrogen receptor-\u03b136 is involved in diallyl sulfide-induced inhibition of malignant growth of HepG2 and Huh7 hepatocellular carcinoma cells. Env. Toxicol. 37, 270\u2013281 (2022).","journal-title":"Env. Toxicol."},{"key":"1021_CR179","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.3390\/molecules25092009","volume":"25","author":"D Delmas","year":"2020","unstructured":"Delmas, D., Xiao, J., Vejux, A. & Aires, V. Silymarin and cancer: a dual strategy in both in chemoprevention and chemosensitivity. Molecules 25, 2009 (2020).","journal-title":"Molecules"},{"key":"1021_CR180","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1039\/C8FO00107C","volume":"9","author":"X Gao","year":"2018","unstructured":"Gao, X. et al. Hepatoprotection of auraptene from peels of citrus fruits against thioacetamide-induced hepatic fibrosis in mice by activating farnesoid X receptor. Food Funct. 9, 2684\u20132694 (2018).","journal-title":"Food Funct."},{"key":"1021_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46891-5","volume":"9","author":"CF Teng","year":"2019","unstructured":"Teng, C. F. et al. Chemopreventive effect of phytosomal curcumin on hepatitis B virus-related hepatocellular carcinoma in a transgenic mouse model. Sci. Rep. 9, 10338 (2019).","journal-title":"Sci. Rep."},{"key":"1021_CR182","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.foodchem.2012.09.063","volume":"136","author":"CF Tsai","year":"2013","unstructured":"Tsai, C. F., Hsu, Y. W., Ting, H. C., Huang, C. F. & Yen, C. C. The in vivo antioxidant and antifibrotic properties of green tea (Camellia sinensis, Theaceae). Food Chem. 136, 1337\u20131344 (2013).","journal-title":"Food Chem."},{"key":"1021_CR183","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jnutbio.2017.10.016","volume":"53","author":"J Li","year":"2018","unstructured":"Li, J. et al. Green tea extract protects against hepatic NF\u03baB activation along the gut-liver axis in diet-induced obese mice with nonalcoholic steatohepatitis by reducing endotoxin and TLR4\/MyD88 signaling. J. Nutr. Biochem. 53, 58\u201365 (2018).","journal-title":"J. Nutr. Biochem."},{"key":"1021_CR184","first-page":"219","volume":"10","author":"PL Kuo","year":"2003","unstructured":"Kuo, P. L. & Lin, C. C. Green tea constituent (\u2212)-epigallocatechin-3-gallate inhibits Hep G2 cell proliferation and induces apoptosis through p53-dependent and Fas-mediated pathways. J. Biomed. Sci. 10, 219\u2013227 (2003).","journal-title":"J. Biomed. Sci."},{"key":"1021_CR185","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1093\/jn\/138.9.1677","volume":"138","author":"M Bose","year":"2008","unstructured":"Bose, M. et al. The major green tea polyphenol, (\u2212)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J. Nutr. 138, 1677\u20131683 (2008).","journal-title":"J. Nutr."},{"key":"1021_CR186","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1017\/S000711450999208X","volume":"102","author":"G Ramadan","year":"2009","unstructured":"Ramadan, G., El-Beih, N. M. & Abd El-Ghffar, E. A. Modulatory effects of black v. green tea aqueous extract on hyperglycaemia, hyperlipidaemia and liver dysfunction in diabetic and obese rat models. Br. J. Nutr. 102, 1611\u20131619 (2009).","journal-title":"Br. J. Nutr."},{"key":"1021_CR187","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s10552-009-9388-x","volume":"20","author":"A Ui","year":"2009","unstructured":"Ui, A. et al. Green tea consumption and the risk of liver cancer in Japan: the Ohsaki Cohort study. Cancer Causes Control. 20, 1939\u20131945 (2009).","journal-title":"Cancer Causes Control."},{"key":"1021_CR188","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/aje\/kwu304","volume":"181","author":"LM Butler","year":"2015","unstructured":"Butler, L. M. et al. Urinary biomarkers of catechins and risk of hepatocellular carcinoma in the Shanghai Cohort Study. Am. J. Epidemiol. 181, 397\u2013405 (2015).","journal-title":"Am. J. Epidemiol."},{"key":"1021_CR189","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1080\/01635581.2023.2178949","volume":"75","author":"J Yu","year":"2023","unstructured":"Yu, J. et al. Coffee, green tea intake, and the risk of hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. Nutr. Cancer 75, 1295\u20131308 (2023).","journal-title":"Nutr. Cancer"},{"key":"1021_CR190","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1002\/ptr.6637","volume":"34","author":"M Mahmoodi","year":"2020","unstructured":"Mahmoodi, M. et al. Effects of green tea or green tea catechin on liver enzymes in healthy individuals and people with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized clinical trials. Phytother. Res. 34, 1587\u20131598 (2020).","journal-title":"Phytother. Res."},{"key":"1021_CR191","doi-asserted-by":"publisher","first-page":"158652","DOI":"10.1016\/j.bbalip.2020.158652","volume":"1865","author":"JY Lim","year":"2020","unstructured":"Lim, J. Y. & Wang, X. D. Mechanistic understanding of \u03b2-cryptoxanthin and lycopene in cancer prevention in animal models. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1865, 158652 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"1021_CR192","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3390\/molecules22060862","volume":"22","author":"J Zeng","year":"2017","unstructured":"Zeng, J. et al. Daucosterol inhibits the proliferation, migration, and invasion of hepatocellular carcinoma cells via Wnt\/\u03b2-catenin signaling. Molecules 22, 862 (2017).","journal-title":"Molecules"},{"key":"1021_CR193","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.3748\/wjg.v16.i15.1937","volume":"16","author":"R Moreno-Otero","year":"2010","unstructured":"Moreno-Otero, R. & Trapero-Marug\u00e1n, M. Hepatoprotective effects of antioxidants in chronic hepatitis C. World J. Gastroenterol. 16, 1937\u20131938 (2010).","journal-title":"World J. Gastroenterol."},{"key":"1021_CR194","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3748\/wjg.v16.i2.184","volume":"16","author":"M Nakamura","year":"2010","unstructured":"Nakamura, M. et al. An antioxidant resveratrol significantly enhanced replication of hepatitis C virus. World J. Gastroenterol. 16, 184\u2013192 (2010).","journal-title":"World J. Gastroenterol."},{"key":"1021_CR195","doi-asserted-by":"publisher","first-page":"14601","DOI":"10.1073\/pnas.251536898","volume":"98","author":"PA Egner","year":"2001","unstructured":"Egner, P. A. et al. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc. Natl Acad. Sci. USA 98, 14601\u201314606 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1021_CR196","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12011-011-9201-z","volume":"145","author":"D Shi","year":"2012","unstructured":"Shi, D. et al. Influence of selenium on hepatic mitochondrial antioxidant capacity in ducklings intoxicated with aflatoxin B1. Biol. Trace Elem. Res. 145, 325\u2013329 (2012).","journal-title":"Biol. Trace Elem. Res."},{"key":"1021_CR197","doi-asserted-by":"publisher","first-page":"77110","DOI":"10.18632\/oncotarget.12804","volume":"7","author":"Z Zhang","year":"2016","unstructured":"Zhang, Z., Bi, M., Liu, Q., Yang, J. & Xu, S. Meta-analysis of the correlation between selenium and incidence of hepatocellular carcinoma. Oncotarget 7, 77110\u201377116 (2016).","journal-title":"Oncotarget"},{"key":"1021_CR198","doi-asserted-by":"publisher","first-page":"S310","DOI":"10.1053\/j.gastro.2004.09.046","volume":"127","author":"TW Kensler","year":"2004","unstructured":"Kensler, T. W. et al. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology 127, S310\u2013S318 (2004).","journal-title":"Gastroenterology"},{"key":"1021_CR199","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11154-023-09853-x","volume":"25","author":"S Rovira-Llopis","year":"2024","unstructured":"Rovira-Llopis, S. et al. Circadian alignment of food intake and glycaemic control by time-restricted eating: a systematic review and meta-analysis. Rev. Endocr. Metab. Disord. 25, 325\u2013337 (2024).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"1021_CR200","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.3390\/nu15234911","volume":"15","author":"T Cresnovar","year":"2023","unstructured":"Cresnovar, T., Habe, G., Jenko Praznikar, Z. & Petelin, A. Effectiveness of time-restricted eating with caloric restriction vs. caloric restriction for weight loss and health: meta-analysis. Nutrients 15, 4911 (2023).","journal-title":"Nutrients"},{"key":"1021_CR201","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.cmet.2018.04.010","volume":"27","author":"EF Sutton","year":"2018","unstructured":"Sutton, E. F. et al. Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. Cell Metab. 27, 1212\u20131221.e3 (2018).","journal-title":"Cell Metab."},{"key":"1021_CR202","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1249\/MSS.0000000000002738","volume":"53","author":"T Moro","year":"2021","unstructured":"Moro, T. et al. Twelve months of time-restricted eating and resistance training improves inflammatory markers and cardiometabolic risk factors. Med. Sci. Sports Exerc. 53, 2577\u20132585 (2021).","journal-title":"Med. Sci. Sports Exerc."},{"key":"1021_CR203","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.3513","volume":"6","author":"X Wei","year":"2023","unstructured":"Wei, X. et al. Effects of time-restricted eating on nonalcoholic fatty liver disease: the TREATY-FLD randomized clinical trial. JAMA Netw. Open. 6, e233513 (2023).","journal-title":"JAMA Netw. Open."},{"key":"1021_CR204","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.cmet.2024.07.004","volume":"36","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. A microbial metabolite inhibits the HIF-2\u03b1-ceramide pathway to mediate the beneficial effects of time-restricted feeding on MASH. Cell Metab. 36, 1823\u20131838.e6 (2024).","journal-title":"Cell Metab."},{"key":"1021_CR205","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1096\/fj.201901147RR","volume":"34","author":"AG Izquierdo","year":"2020","unstructured":"Izquierdo, A. G. et al. An energy restriction-based weight loss intervention is able to reverse the effects of obesity on the expression of liver tumor-promoting genes. FASEB J. 34, 2312\u20132325 (2020).","journal-title":"FASEB J."},{"key":"1021_CR206","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/jnci\/djz111","volume":"111","author":"SE Baumeister","year":"2019","unstructured":"Baumeister, S. E., Leitzmann, M. F., Linseisen, J. & Schlesinger, S. Physical activity and the risk of liver cancer: a systematic review and meta-analysis of prospective studies and a bias analysis. J. Natl Cancer Inst. 111, 1142\u20131151 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"1021_CR207","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000108","volume":"7","author":"JG Stine","year":"2023","unstructured":"Stine, J. G. et al. American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease. Hepatol. Commun. 7, e0108 (2023).","journal-title":"Hepatol. Commun."},{"key":"1021_CR208","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1054\/bjoc.2000.1580","volume":"84","author":"Y Ito","year":"2001","unstructured":"Ito, Y. et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br. J. Cancer 84, 1377\u20131383 (2001).","journal-title":"Br. J. Cancer"},{"key":"1021_CR209","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/ncb3031","volume":"16","author":"H Lanaya","year":"2014","unstructured":"Lanaya, H. et al. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat. Cell Biol. 16, 972\u2013977 (2014).","journal-title":"Nat. Cell Biol."},{"key":"1021_CR210","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/hep.20538","volume":"41","author":"E Schiffer","year":"2005","unstructured":"Schiffer, E. et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41, 307\u2013314 (2005).","journal-title":"Hepatology"},{"key":"1021_CR211","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210828","volume":"14","author":"S Choung","year":"2019","unstructured":"Choung, S. et al. Epidermal growth factor receptor inhibition attenuates non-alcoholic fatty liver disease in diet-induced obese mice. PLoS ONE 14, e0210828 (2019).","journal-title":"PLoS ONE"},{"key":"1021_CR212","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bbadis.2017.10.016","volume":"1864","author":"D Liang","year":"2018","unstructured":"Liang, D. et al. Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 133\u2013142 (2018).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"1021_CR213","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00418-020-01867-9","volume":"154","author":"H Xu","year":"2020","unstructured":"Xu, H. et al. EGF neutralization antibodies attenuate liver fibrosis by inhibiting myofibroblast proliferation in bile duct ligation mice. Histochem. Cell Biol. 154, 107\u2013116 (2020).","journal-title":"Histochem. Cell Biol."},{"key":"1021_CR214","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092273","volume":"9","author":"I Nakamura","year":"2014","unstructured":"Nakamura, I. et al. Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling. PLoS ONE 9, e92273 (2014).","journal-title":"PLoS ONE"},{"key":"1021_CR215","doi-asserted-by":"publisher","first-page":"894","DOI":"10.7150\/thno.21168","volume":"8","author":"YC Sung","year":"2018","unstructured":"Sung, Y. C. et al. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. Theranostics 8, 894\u2013905 (2018).","journal-title":"Theranostics"},{"key":"1021_CR216","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.bbrc.2021.09.036","volume":"578","author":"L Xu","year":"2021","unstructured":"Xu, L. et al. Persistent mTORC1 activation via Depdc5 deletion results in spontaneous hepatocellular carcinoma but does not exacerbate carcinogen- and high-fat diet-induced hepatic carcinogenesis in mice. Biochem. Biophys. Res. Commun. 578, 142\u2013149 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1021_CR217","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/1940-6207.CAPR-20-0220","volume":"14","author":"MD Gay","year":"2021","unstructured":"Gay, M. D. et al. Targeting the cholecystokinin receptor: a novel approach for treatment and prevention of hepatocellular cancer. Cancer Prev. Res. 14, 17\u201330 (2021).","journal-title":"Cancer Prev. Res."},{"key":"1021_CR218","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.3390\/ijms241411546","volume":"24","author":"K Yamada","year":"2023","unstructured":"Yamada, K. et al. Suppression of NASH-related HCC by farnesyltransferase inhibitor through inhibition of inflammation and hypoxia-inducible factor-1\u03b1 expression. Int. J. Mol. Sci. 24, 1546 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1021_CR219","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/mc.22818","volume":"57","author":"ML Dechassa","year":"2018","unstructured":"Dechassa, M. L. et al. Identification of chromatin-accessible domains in non-alcoholic steatohepatitis-derived hepatocellular carcinoma. Mol. Carcinog. 57, 978\u2013987 (2018).","journal-title":"Mol. Carcinog."},{"key":"1021_CR220","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/gutjnl-2019-318918","volume":"70","author":"F J\u00fchling","year":"2021","unstructured":"J\u00fchling, F. et al. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut 70, 157\u2013169 (2021).","journal-title":"Gut"},{"key":"1021_CR221","unstructured":"US Food and Drug Administration. FDA approves first treatment for patients with liver scarring due to fatty lier disease. FDA www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease (2024)."},{"key":"1021_CR222","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497\u2013509 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1021_CR223","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ijbiomac.2020.02.287","volume":"152","author":"NH AbdelAllah","year":"2020","unstructured":"AbdelAllah, N. H. et al. Alginate-coated chitosan nanoparticles act as effective adjuvant for hepatitis A vaccine in mice. Int. J. Biol. Macromol. 152, 904\u2013912 (2020).","journal-title":"Int. J. Biol. Macromol."},{"key":"1021_CR224","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12985-017-0753-1","volume":"14","author":"MH Elberry","year":"2017","unstructured":"Elberry, M. H., Darwish, N. H. E. & Mousa, S. A. Hepatitis C virus management: potential impact of nanotechnology. Virol. J. 14, 88 (2017).","journal-title":"Virol. J."},{"key":"1021_CR225","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3390\/vaccines9060558","volume":"9","author":"N Pippa","year":"2021","unstructured":"Pippa, N., Gazouli, M. & Pispas, S. Recent advances and future perspectives in polymer-based nanovaccines. Vaccines 9, 558 (2021).","journal-title":"Vaccines"},{"key":"1021_CR226","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00813-3","volume":"9","author":"H Zhao","year":"2024","unstructured":"Zhao, H. et al. A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression. NPJ Vaccines 9, 22 (2024).","journal-title":"NPJ Vaccines"},{"key":"1021_CR227","doi-asserted-by":"publisher","first-page":"873160","DOI":"10.3389\/fmicb.2022.873160","volume":"13","author":"W Luo","year":"2022","unstructured":"Luo, W. et al. Hepatocellular carcinoma: how the gut microbiota contributes to pathogenesis, diagnosis, and therapy. Front. Microbiol. 13, 873160 (2022).","journal-title":"Front. Microbiol."},{"key":"1021_CR228","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nrgastro.2017.72","volume":"14","author":"LX Yu","year":"2017","unstructured":"Yu, L. X. & Schwabe, R. F. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat. Rev. Gastroenterol. Hepatol. 14, 527\u2013539 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1021_CR229","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/gut.2009.183749","volume":"59","author":"JG Fox","year":"2010","unstructured":"Fox, J. G. et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 59, 88\u201397 (2010).","journal-title":"Gut"},{"key":"1021_CR230","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/jnci\/86.16.1222","volume":"86","author":"JM Ward","year":"1994","unstructured":"Ward, J. M. et al. Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel Helicobacter species. J. Natl Cancer Inst. 86, 1222\u20131227 (1994).","journal-title":"J. Natl Cancer Inst."},{"key":"1021_CR231","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41575-023-00771-6","volume":"20","author":"O Pabst","year":"2023","unstructured":"Pabst, O. et al. Gut-liver axis: barriers and functional circuits. Nat. Rev. Gastroenterol. Hepatol. 20, 447\u2013461 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1021_CR232","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ccr.2012.02.007","volume":"21","author":"DH Dapito","year":"2012","unstructured":"Dapito, D. H. et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21, 504\u2013516 (2012).","journal-title":"Cancer Cell"},{"key":"1021_CR233","doi-asserted-by":"publisher","first-page":"1145392","DOI":"10.3389\/fendo.2023.1145392","volume":"14","author":"C Huang","year":"2023","unstructured":"Huang, C. et al. Pattern recognition receptors in the development of nonalcoholic fatty liver disease and progression to hepatocellular carcinoma: an emerging therapeutic strategy. Front. Endocrinol. 14, 1145392 (2023).","journal-title":"Front. Endocrinol."},{"key":"1021_CR234","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nature12347","volume":"499","author":"S Yoshimoto","year":"2013","unstructured":"Yoshimoto, S. et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499, 97\u2013101 (2013).","journal-title":"Nature"},{"key":"1021_CR235","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7818","volume":"6","author":"CL Wilson","year":"2015","unstructured":"Wilson, C. L. et al. NFkappaB1 is a suppressor of neutrophil-driven hepatocellular carcinoma. Nat. Commun. 6, 6818 (2015).","journal-title":"Nat. Commun."},{"key":"1021_CR236","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2019.07.028","volume":"157","author":"A Moeini","year":"2019","unstructured":"Moeini, A. et al. An immune gene expression signature associated with development of human hepatocellular carcinoma identifies mice that respond to chemopreventive agents. Gastroenterology 157, 1383\u20131397.e11 (2019).","journal-title":"Gastroenterology"},{"key":"1021_CR237","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41575-021-00520-7","volume":"19","author":"A Albillos","year":"2022","unstructured":"Albillos, A. et al. Cirrhosis-associated immune dysfunction. Nat. Rev. Gastroenterol. Hepatol. 19, 112\u2013134 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1021_CR238","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/hep.23173","volume":"50","author":"R Kassel","year":"2009","unstructured":"Kassel, R. et al. Chronically inflamed livers up-regulate expression of inhibitory B7 family members. Hepatology 50, 1625\u20131637 (2009).","journal-title":"Hepatology"},{"key":"1021_CR239","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","volume":"138","author":"P Fisicaro","year":"2010","unstructured":"Fisicaro, P. et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138, 682\u2013693 (2010).","journal-title":"Gastroenterology"},{"key":"1021_CR240","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1053\/j.gastro.2015.11.050","volume":"150","author":"JJ Park","year":"2016","unstructured":"Park, J. J. et al. Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology 150, 684\u2013695.e5 (2016).","journal-title":"Gastroenterology"},{"key":"1021_CR241","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021: towards ending viral hepatitis. WHO iris.who.int\/bitstream\/handle\/10665\/246177\/WHO-HIV-2016.06-eng.pdf (2016)."},{"key":"1021_CR242","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90, 1371\u20131388 (1998).","journal-title":"J. Natl Cancer Inst."},{"key":"1021_CR243","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel, V. G. et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295, 2727\u20132741 (2006).","journal-title":"JAMA"},{"key":"1021_CR244","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa030660","volume":"349","author":"IM Thompson","year":"2003","unstructured":"Thompson, I. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215\u2013224 (2003).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-01021-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-01021-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-01021-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T08:13:07Z","timestamp":1740730387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-01021-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":244,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1021"],"URL":"https:\/\/doi.org\/10.1038\/s41575-024-01021-z","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]},"assertion":[{"value":"7 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.D.Y. provides a consulting service for AstraZeneca, Eisai, Exact Sciences, Exelixis, Fujifilm Medical Sciences, Merck and Gilead Sciences. A.V. has received consulting fees from FirstWorld, Pioneering Medicine and Genentech; advisory board fees from BMS, Roche, AstraZeneca, Eisai and NGM Pharmaceuticals; research support from Eisai; and has stock options from Espervita. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}